Adjuvants

P02.01
Specific IgA Plasma Cell Recruitment to the Female Genital Tract Following Intravaginal Administration of CCL28 or MPLA

V Buffa
P02.02
Vaccine Antigen Immunity Is Enhanced by Optimized TLR4 and TLR7/8 Adjuvant Combinations in Mini-Pigs Inoculated via a Systemic but Not a Mucosal Route

PF McKay, DF King, D Carter, RJ Shattock
P02.03
A Comparative Analysis of HIV-Specific Immunity Following DNA Co-Immunisation with Different Adjuvants

J Hou
P02.04
A Novel Glycolipid Adjuvant Significantly Boosts Cellular Immune Responses to an Adenoviral Vaccine in Non Human Primates

S Vasan, M Boente-Carrera, J McManus, NN Padte, A Gettie, BF Grasperge, N Patterson, CD Andrews, T Richie, M Tsuji
P02.05
Co-Administration of NOD1 and NOD2 Ligands with HIV-1 p24 Increase Mucosal Immune Potency of Biodegradable Nanocarriers

V Pavot, N Rochereau, C Genin, E Perouzel, G Tiraby, T Delaire, S Paul, B Verrier
P02.06
Liposomes Containing Glucosyl Ceramide and the Adjuvant Monophosphoryl Lipid A Specifically Bind T4 Bacteriophage: A Self-Assembling Nanocarrier

KK Peachman, O Jobe, L Wieczorek, L Asher, VR Polonis, V Rao, CR Alving, M Rao
P02.07
Antigen-Specific Enhancement of Natural Human IgG Antibodies to Lipids Induced by a Liposomal Vaccine Containing Lipid A and a Protein Antigen

GR Matyas, CR Alving
P02.08
GM-CSF as an Adjuvant for MVA Vaccine: High Dose but Not Low Dose Inhibits T Cell Responses and Rectal IgA by Modulating DC Activation and Phenotype

R Amara, S Kannanganat, L Lai, S Gangadhara, S Kwa, P Kozlowski, V Hirsch, LS Wyatt, PL Earl, B Moss, HL Robinson
P02.09
Polyethyleneimine Is a Potent Mucosal Adjuvant and Candidate Adjuvant for HIV-1 Vaccination

S Brinckmann, F Wegmann, K Gartlan, Q Sattentau
P02.10
Degradable PEI Form as Safer Alternative for HIV-1 Vaccine Development and Adjuvant Potency as a Common Trait of Oligoethyleneimines

S Brinckmann, F Wegmann, K Gartlan, Q Sattentau